9
Jan
2020
MRNA Vaccines Impress, Blueprint Wins First FDA OK, & Calif. Gov. Stares Down Biotech on the Eve of #JPM20
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2019
Designer Proteins as Better Therapies: David Baker on The Long Run
Today’s guest on The Long Run is David Baker. David is a biochemistry professor at the University of Washington, a Howard Hughes Medical Institute investigator, and the director of The Institute for Protein Design at the University of Washington. Just like the name suggests, this institute works on designing proteins with special properties. Sometimes these proteins are designed on computers,... Read More
3
Dec
2019
Sticking With Epigenetics During Lean Times: Jigar Raythatha on The Long Run
Today’s guest on The Long Run is Jigar Raythatha. Jigar is the CEO of Cambridge, Mass.-based Constellation Pharmaceuticals. This company is built to develop drugs against epigenetic targets. Simply put, this is a way to turn genes on or off without altering the underlying DNA. The pharmaceutical industry fancied this idea about a decade ago, as a way to shut... Read More
2
Dec
2019
IFM, Staying Small, Raises (Merely) $55.5M, Promotes Former Novartis Exec to CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Nov
2019
Tamping Down Inflammation & Synaptic Dysfunction in Alzheimer’s: John Alam on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2019
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee... Read More
7
Nov
2019
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2019
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Oct
2019
The Story of Henri Termeer: John Hawkins and Jim Geraghty on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2019
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2019
Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Oct
2019
Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Oct
2019
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2019
12 VCs Who Matter, But You Hardly Ever Read About
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re... Read More
3
Oct
2019
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Oct
2019
From Farm Field to MIT Lab: Phil Sharp on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2019
Big IPO Week On Deck, Amazon & Walmart Health Moves, & Akcea Exec Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Sep
2019
Speaker Pelosi’s Envisioned Drug Price Clampdown, Lundbeck’s Move into Migraine, & Diabetes Drug-Device Pairings
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.